About Us
Transforming biopharma manufacturing through precision engineered process solutions
Our Vision
To simplify and elevate biomanufacturing worldwide by providing ready-to-use process solutions that accelerate development, reduce complexity, and empower teams to focus on science, not preparation.
Our Mission
To deliver high-quality, ready-to-use buffers and process liquids that remove preparation burdens, enhance consistency, and accelerate biomanufacturing enabling our partners to bring life-changing therapies to patients more efficiently.
Who We Are
Sanra Biosciences develops and supplies ready-to-use buffers, process liquids, and water solutions for the biopharmaceutical and life sciences industries.
Our goal is simple. We want to remove the hidden bottlenecks in biomanufacturing by providing custom solutions that are delivered when and how you need them.
Our manufacturing plant in Ahmedabad, Gujarat, India, is built to cGMP design standards and will be certified under ISO 9001, 14001, and 45001. With in-house WFI generation, aseptic filling rooms, and environmental monitoring systems, we ensure every product is produced under controlled conditions. Learn more about our technical capabilities.
Our Founders
Sanaya Bharadia
Pharmacologist
Our Story
The founding of Sanra Biosciences was sparked by a driving curiosity about where true value could be unlocked within the complex biopharma supply chain.
Sanaya and Raj observed countless resources like time, specialised labour, and valuable cleanroom space being dedicated to the meticulous yet routine preparation of buffers. They began asking a pivotal question: "If high-purity components like media and resins are routinely sourced from specialists, why do we treat buffer preparation as a mere internal chore? What level of quality and efficiency could be achieved if a dedicated expert focused on buffer preparation alone?"
This thought kickstarted the vision for Sanra Biosciences: a specialised partner dedicated to perfecting auxiliary solutions and guaranteeing pharmaceutical-grade consistency and sterility at scale. Sanaya and Raj saw an opportunity to transform a resource-intensive task into a ready-to-use, risk-free solution, allowing the industry to redirect its focus entirely toward breakthrough science.